← All trials
NCT00354302
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2006
- Primary completion
- Mar 1, 2011
- Completion date
- Mar 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 497
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- Mayo ClinicStudy chair
- Herbert Irving Comprehensive Cancer CenterStudy chair
- Harvard UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- Southwest Oncology GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.